Diamine derivatives

Abstract

A compound represented by the general formula (1): -Q 1 -Q 2 -T 0 -N(R 1 )-Q 3 -(R 2 )T 1 Q 4   (1) wherein R 1 and R 2 are hydrogen atoms or the like; Q 1 is a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may be substituted, or the like; Q 2 is a single bond or the like; Q 3 is a group in which Q 5 is an alkylene group having 1 to 8 carbon atoms, or the like; and T 0 and T 1 are carbonyl groups or the like; a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

1 - 59 . (canceled) 
     
     
         60 . A method for treating thrombosis or embolism, the method comprising administering to a patient in need thereof an effective amount of N 1 -(5-chloropyridin-2-yl)-N 2 -(4-[(dimethylamino)carbonyl]-2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino}cyclohexyl)ethanediamide, represented by Formula (I), or a salt thereof: 
       
         
           
           
               
               
           
         
       
     
     
         61 . A method for treating thrombosis or embolism, the method comprising administering to a patient in need thereof an effective amount of N 1 -(5-chloropyridin-2-yl)-N 2 -(4-[(dimethylamino)carbonyl]-2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino}cyclohexyl)ethanediamide p-toluenesulfonate, represented by Formula (II): 
       
         
           
           
               
               
           
         
       
     
     
         62 . A method for treating thrombosis or embolism, the method comprising administering to a patient in need thereof an effective amount of N 1 -(5-chloropyridin-2-yl)-N 2 -(4-[(dimethylamino)carbonyl]-2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino}cyclohexyl)ethanediamide p-toluenesulfonate monohydrate, represented by Formula (III): 
       
         
           
           
               
               
           
         
       
     
     
         63 . A method for treating thrombosis or embolism, the method comprising administering to a patient in need thereof an effective amount of N 1 -(5-chloropyridin-2-yl)-N 2 -((1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino}cyclohexyl)ethanediamide, represented by Formula (IV), or a salt thereof: 
       
         
           
           
               
               
           
         
       
     
     
         64 . A method for treating thrombosis or embolism, the method comprising administering to a patient in need thereof an effective amount of N 1 -(5-chloropyridin-2-yl)-N 2 -((1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino}cyclohexyl)ethanediamide p-toluenesulfonate, represented by Formula (V): 
       
         
           
           
               
               
           
         
       
     
     
         65 . A method for treating thrombosis or embolism, the method comprising administering to a patient in need thereof an effective amount of N 1 -(5-chloropyridin-2-yl)-N 2 -((1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino}cyclohexyl)ethanediamide p-toluenesulfonate monohydrate, represented by Formula (VI): 
       
         
           
           
               
               
           
         
       
     
     
         66 . A method for treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary embolism, deep venous thrombosis, thrombus formation after valve or joint replacement, or thrombus formation and reocclusion after angioplasty, the method comprising administering to a patient in need thereof an effect amount of N 1 -(5-chloropyridin-2-yl)-N 2 -(4-[(dimethylamino)carbonyl]-2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino}cyclohexyl)ethanediamide, represented by Formula (I), or a salt thereof: 
       
         
           
           
               
               
           
         
       
     
     
         67 . A method for treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary embolism, deep venous thrombosis, thrombus formation after valve or joint replacement, or thrombus formation and reocclusion after angioplasty, the method comprising administering to a patient in need thereof an effect amount of N 1 -(5-chloropyridin-2-yl)-N 2 -(4-[(dimethylamino)carbonyl]-2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino}cyclohexyl)ethanediamide p-toluenesulfonate, represented by Formula (II): 
       
         
           
           
               
               
           
         
       
     
     
         68 . A method for treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary embolism, deep venous thrombosis, thrombus formation after valve or joint replacement, or thrombus formation and reocclusion after angioplasty, the method comprising administering to a patient in need thereof an effect amount of N 1 -(5-chloropyridin-2-yl)-N 2 -(4-[(dimethylamino)carbonyl]-2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino}cyclohexyl)ethanediamide p-toluenesulfonate monohydrate, represented by Formula (III): 
       
         
           
           
               
               
           
         
       
     
     
         69 . A method for treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary embolism, deep venous thrombosis, thrombus formation after valve or joint replacement, or thrombus formation and reocclusion after angioplasty, the method comprising administering to a patient in need thereof an effect amount of N 1 -(5-chloropyridin-2-yl)-N 2 -((1 S,2R,4S)-4-[(dimethylamino)carbonyl]-2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino}cyclohexyl)ethanediamide, represented by Formula (IV), or a salt thereof: 
       
         
           
           
               
               
           
         
       
     
     
         70 . A method for treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary embolism, deep venous thrombosis, thrombus formation after valve or joint replacement, or thrombus formation and reocclusion after angioplasty, the method comprising administering to a patient in need thereof an effect amount of N 1 -(5-chloropyridin-2-yl)-N 2 -((1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino}cyclohexyl)ethanediamide p-toluenesulfonate, represented by Formula (V): 
       
         
           
           
               
               
           
         
       
     
     
         71 . A method for treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary embolism, deep venous thrombosis, thrombus formation after valve or joint replacement, or thrombus formation and reocclusion after angioplasty, the method comprising administering to a patient in need thereof an effect amount of N 1 -(5-chloropyridin-2-yl)-N 2 -((1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino}cyclohexyl)ethanediamide p-toluenesulfonate monohydrate, represented by Formula (VI):